Pharmicell
Key metrics
Earnings
| Revenue, Q3 2026 | ₩37.0bn |
|---|---|
| Revenue QoQ | -5.2% |
| Revenue YoY | +44.1% |
| Operating income, Q3 2026 | ₩11.9bn |
| Operating income QoQ | -9.8% |
| Operating income YoY | +46.6% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | 0.0% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩39.6bn |
|---|---|
| Supply contracts vs prior-year revenue | 34.7% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 3 |
|---|---|
| DART filings, previous 3 months | 13 |
Insider transactions
| Open-market buys, last 12 months (shares) | 14,000 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩194m |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 14,000 shares |
| Insiders who bought, last 12 months | 1 |
Insider transactions (last 12 months)
Open-market buys: 14,000 shares (₩194m). Open-market sells: 0 shares (₩0). Net open-market buying: +14,000 shares. Insiders who bought: 1.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | Kim Su-chan (Registered director) | Other (Other increase) | +668 shares | — | — | |
| Jun 16, 2026 | Jung Sun-ung (Non-registered officer) | Other (Other increase) | +668 shares | — | — | |
| Jun 16, 2026 | Jang Hak-sun (Non-registered officer) | Other (Other increase) | +668 shares | — | — | |
| Jun 16, 2026 | Lim Yeong-ja (Non-registered officer) | Other (Other increase) | +668 shares | — | — | |
| Jun 16, 2026 | Bae Ui-han (Non-registered officer) | Other (Other increase) | +668 shares | — | — | |
| Jun 16, 2026 | Sung Hyeon-sul (Non-registered officer) | Other (Other increase) | +668 shares | — | — | |
| Jan 28, 2026 | Kim Hyeon-su (Registered director) | Open-market buy | +14,000 shares | ₩13,831 | ₩194m | |
| Jan 13, 2026 | Sung Hyeon-sul (Non-registered officer) | Other (New appointment) | +978 shares | — | — |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩114.1bn | ₩34.3bn |
| 2024 | ₩64.9bn | ₩4.7bn |
| 2023 | ₩56.2bn | ₩1.3bn |
Filing timeline
-
Pharmicell signs ₩7.4bn electronic materials supply contract with Doosan
Pharmicell disclosed a supply contract for electronic materials with counterparty Doosan Corporation, which the filing reports as 6.5% of revenue. The contract amount is ₩7.4bn, with a period from Oct 13, 2026 to Dec 31, 2026.